Abstract Search

ea0089c6 | Clinical – Chemo/SSA/Biologics | NANETS2022

An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

Eads, MD Jennifer R. , Das, MD Satya , Li, MD Daneng , Mohamed, MD Amr , Tucci, MBS, CCRP Christopher , Nanda, MS Shivani , Kauh, MD, FACP John S. , Kania, MD, MBA Marek K. , Dasari, MD Arvind

Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...

0 shares

Endocrine Abstracts

An Open-Label, Phase 1b/2 study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Neuroendocrine Tumors

BiosciAbstracts